ALFA FinderNSE filing, NSE: BETA. Summary written from the filing by ALFA Finder's alert engine.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,805.90
- Market cap
- ₹2,002 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 38.6×Sector 43.0×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Q2 FY27 Results: Net Profit ₹18.55 Cr, Up 51.8% YoY
Beta Drugs Ltd reported revenue from operations of ₹137.5 Cr (+33.0% YoY) and net profit of ₹18.55 Cr (+51.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.55 Cr · +51.8% YoY
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Beta Drugs Annual General Meeting
Beta Drugs Limited conducted its 21st Annual General Meeting on September 30, 2026. Shareholders considered resolutions including financial statement adoption, director re-appointments, and auditor ratification.
Other capital structure change announcements
All →Tata Steel Capital Structure Change
Tata Steel's stake in subsidiary CPDPL rose from 51% to 57.5% via conversion of preference shares. CPDPL remains a subsidiary; no fresh capital was subscribed.
Filatex India Capital Structure Change
Filatex India invested Rs.13.00 Crore by subscribing 1.30 crore rights shares of wholly owned subsidiary Ecosis at Rs.10. Funds support the polyester recycling project, loan repayment and working capital.
- Value
- ₹13.00 Cr
Zydus Lifesciences Capital Structure Change
LIC sold 20,242,068 Zydus Lifesciences shares via market sale, cutting its stake from 5.21 percent to 3.18 percent. Non-promoter SAST disclosure covering 28.08.2025 to 05.11.2026.
Indian Oil Corporation Capital Structure Change
LIC, a non-promoter shareholder, reported a market sale of 28,34,86,368 shares in Indian Oil, cutting its holding from 7.887% to 5.879%. No monetary value is stated.
- Promoter stake change
- -2.01%
Kirloskar Oil Engines Capital Structure Change
Kirloskar Oil Engines signed a shareholders' agreement with TPG for its subsidiary Arka Fincap. TPG's investment totals ₹800 Crore across two tranches, the second conditional.
- Value
- ₹800.0 Cr
Ace Software Exports Ltd Partly Paidup Capital Structure Change
Ace Software Exports approved a ₹30.25 second and final call on 54,71,101 partly paid shares. The record date is 20 November 2026.
- Value
- ₹16.55 Cr